Trulicity vs Ozempic, Mounjaro, Wegovy & Zepbound

Molecule and potency. Trulicity is dulaglutide, a larger GLP-1 analog fused to a human antibody fragment. Ozempic is semaglutide, a smaller modified peptide. On a dose-for-dose basis, semaglutide produces greater GLP-1 receptor activation and — in head-to-head trials — greater A1c reduction and weight loss than dulaglutide. Both are given once weekly by subcutaneous injection.

Ozempic wins on mean weight loss across dose-matched comparisons. In SUSTAIN-7, semaglutide 1.0 mg produced approximately 6.5 kg of weight loss at 40 weeks, versus 3.0 kg for dulaglutide 1.5 mg. At maximum doses (Trulicity 4.5 mg vs Ozempic 2.0 mg), Ozempic still produces somewhat greater mean weight loss, though both are substantially outperformed by Mounjaro/Zepbound (tirzepatide) and by Wegovy (higher-dose semaglutide).

In head-to-head data, semaglutide produces slightly greater A1c reduction than dulaglutide at comparable doses. Both are highly effective diabetes medications — a typical patient can expect roughly a 1.0–1.8% A1c reduction, depending on starting A1c, dose, and baseline therapy.

The side-effect profiles are very similar. Both can cause nausea, vomiting, diarrhea, constipation, and injection-site reactions, with GI effects peaking during dose escalation and usually improving over time. Both carry a boxed warning about the risk of thyroid C-cell tumors based on animal studies. Pancreatitis and gallbladder disease are listed as rare but serious risks for both. Individual tolerability varies — some patients tolerate one molecule but not the other.

Trulicity's pen is a single-use auto-injector with a hidden needle and no dose dial — you press it against your skin and it delivers the full weekly dose with two clicks. Many patients describe it as the simplest GLP-1 pen to self-administer. Ozempic uses a multi-dose pen: you dial the dose, attach a new needle, and inject. The Ozempic pen is more efficient per unit of waste but requires more steps. Preference is personal.

Mounjaro. In the SURPASS-3 trial, tirzepatide reduced A1c by roughly 2.0–2.4% depending on dose, compared to approximately 1.3% for insulin degludec (a direct comparator in that study). Against Trulicity specifically, tirzepatide produced greater A1c reduction and greater weight loss at every comparable dose level.

Mounjaro significantly outperforms Trulicity. At its 15 mg maximum, tirzepatide produced an average of roughly 22 lb (about 10 kg) additional weight loss beyond what Trulicity 4.5 mg achieves. This is why many patients — and clinicians — now prefer tirzepatide when weight loss is part of the goal.

Both can cause nausea, vomiting, diarrhea, and decreased appetite, with GI effects most intense during dose escalation. Mounjaro's GI side effects tend to be slightly more pronounced at higher doses (10 mg and above) because of the larger overall weight loss and stronger appetite suppression. Both share the same class warnings about thyroid C-cell tumors, pancreatitis, and gallbladder disease.

Yes, under medical supervision, and this is an increasingly common switch. The standard approach is to stop Trulicity and begin Mounjaro at the 2.5 mg introductory dose for at least four weeks, regardless of the previous Trulicity dose. After that, the dose is titrated based on response and tolerability. Do not self-switch.

Different molecules, different purposes. Trulicity is dulaglutide — a GLP-1 drug approved for type 2 diabetes. Wegovy is semaglutide dosed at 2.4 mg weekly — also a GLP-1 drug, but approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related health condition. Wegovy is the same molecule as Ozempic but at a higher weight-optimized dose.

In the STEP-1 trial, Wegovy patients lost an average of 14.9% of body weight at 68 weeks — about 15 kg for a 100 kg patient. In Trulicity's AWARD-11 trial, the 4.5 mg dose produced an average of 4.6 kg at 52 weeks. For a patient whose primary goal is weight reduction, Wegovy is several times more effective on average.

Only in patients who also have type 2 diabetes — and even then, the decision should be driven by diabetes control, not weight loss. Trulicity has no weight management indication; prescribing it specifically for weight loss in a non-diabetic patient is off-label, uncovered by insurance, and clinically inferior to Wegovy for that purpose.

Zepbound activates both the GIP and GLP-1 receptors (dual agonist), while Trulicity activates only GLP-1. Zepbound is titrated up to 15 mg weekly for weight management. In SURMOUNT-1, Zepbound produced mean weight loss of roughly 20% of body weight at 72 weeks on the 15 mg dose — about four times the mean weight loss seen with Trulicity 4.5 mg.

Zepbound is not approved for diabetes (that's Mounjaro's role). If you have type 2 diabetes, your options are Trulicity, Ozempic, Mounjaro, Victoza, or other non-GLP-1 diabetes drugs. A licensed clinician can discuss whether the better trajectory for you is Mounjaro (for diabetes + weight) or Zepbound (if the diabetes is well controlled and weight is the driver).

Victoza is a once-daily injection; Trulicity is once-weekly. For most patients, the weekly schedule is significantly more convenient — 52 injections per year instead of 365. In head-to-head trials (AWARD-6), Trulicity 1.5 mg produced similar A1c reduction to Victoza 1.8 mg and similar weight loss.

Victoza has a longer post-marketing safety record and is approved for pediatric type 2 diabetes in patients as young as 10. Its daily titration can also be useful for patients who experience severe nausea on weekly drugs, since the shorter-acting liraglutide washes out more quickly if the dose needs to be lowered.